The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

The atrial fibrillation (AF) device market is experiencing rapid growth, fueled by the rising prevalence of atrial fibrillation, increasing awareness of early diagnosis, and advancements in medical ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

A new treatment at Unity Point Health is offering promising results for those with irregular heartbeats, otherwise known as ...

If you struggle with atrial fibrillation, evolving technologies at United Regional may be able to help your heart stay ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

WAUSAU, Wis. (WSAW) - A free seminar is being held Wednesday evening in Wausau to educate people about AFib. Atrial ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

The FDA submission is backed by robust data from the VALID-ECG pivotal study, which enrolled 198 patients across five clinical sites. The Company believes the study's findings support the clinical ...